We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Chevron, AstraZeneca, Netflix, Medtronic and Marvell Technology
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 11, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron Corporation (CVX - Free Report) , AstraZeneca PLC (AZN - Free Report) , Netflix, Inc. (NFLX - Free Report) , Medtronic plc (MDT - Free Report) and Marvell Technology, Inc. (MRVL - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Chevron, AstraZeneca and Netflix
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation, AstraZeneca PLC and Netflix, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Chevron have gained +8.0% over the past year against the Zacks Oil and Gas - Integrated - International industry’s gain of +17.8%. The company is considered one of the best-placed global integrated oil firms to achieve sustainable production ramp-up.
America’s No. 2 energy firm’s existing project pipeline is among the best in the industry, thanks to its premier position in the lucrative Permian Basin. However, Chevron was not immune to the commodity price crash of 2020, forcing it to cut spending substantially.
The company’s high oil price sensitivity is a concern too. Moreover, the supermajor’s 10-year reserve replacement ratio of 100% is indicative of its inability to replace the amount of energy produced.
AstraZeneca’s shares have gained +14.1% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +25.7%. The company enjoys a diverse product portfolio and a global footprint. AstraZeneca’s key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra and Farxiga should keep driving revenues.
Almost all non-COVID therapy areas of AstraZeneca demonstrated double-digit revenue growth in the first half of 2023. Its pipeline is strong with important phase III data readouts lined up. It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets.
The Alexion buyout has added drugs like Ultomiris that are boosting its top line. However, AstraZeneca’s diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit. Sales have slowed down in its key market, China.
Shares of Netflix have outperformed the Zacks Broadcast Radio and Television industry over the year-to-date period (+50.3% vs. +25.5%). The company is benefiting from growing subscriber base thanks to a robust portfolio. Crackdown on password-sharing and the introduction of paid sharing in more than 100 countries, which represents more than 80% of Netflix’s revenue base, is also expected to aid growth.
Netflix’s diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content, has been driving its growth prospects. It now expects revenue growth to accelerate in the second half of 2023.
Nevertheless, stiff competition in the streaming space from the likes of Apple, Amazon Prime Video, HBO Max, Disney+, Peacock, Paramount+ and TikTok is a headwind. Netflix’s leveraged balance sheet and a higher streaming obligation are concerns.
Other noteworthy reports we are featuring today include Medtronic plc and Marvell Technology, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Chevron, AstraZeneca, Netflix, Medtronic and Marvell Technology
For Immediate Release
Chicago, IL – September 11, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron Corporation (CVX - Free Report) , AstraZeneca PLC (AZN - Free Report) , Netflix, Inc. (NFLX - Free Report) , Medtronic plc (MDT - Free Report) and Marvell Technology, Inc. (MRVL - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Chevron, AstraZeneca and Netflix
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation, AstraZeneca PLC and Netflix, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Chevron have gained +8.0% over the past year against the Zacks Oil and Gas - Integrated - International industry’s gain of +17.8%. The company is considered one of the best-placed global integrated oil firms to achieve sustainable production ramp-up.
America’s No. 2 energy firm’s existing project pipeline is among the best in the industry, thanks to its premier position in the lucrative Permian Basin. However, Chevron was not immune to the commodity price crash of 2020, forcing it to cut spending substantially.
The company’s high oil price sensitivity is a concern too. Moreover, the supermajor’s 10-year reserve replacement ratio of 100% is indicative of its inability to replace the amount of energy produced.
(You can read the full research report on Chevron here >>>)
AstraZeneca’s shares have gained +14.1% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +25.7%. The company enjoys a diverse product portfolio and a global footprint. AstraZeneca’s key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra and Farxiga should keep driving revenues.
Almost all non-COVID therapy areas of AstraZeneca demonstrated double-digit revenue growth in the first half of 2023. Its pipeline is strong with important phase III data readouts lined up. It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets.
The Alexion buyout has added drugs like Ultomiris that are boosting its top line. However, AstraZeneca’s diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit. Sales have slowed down in its key market, China.
(You can read the full research report on AstraZeneca here >>>)
Shares of Netflix have outperformed the Zacks Broadcast Radio and Television industry over the year-to-date period (+50.3% vs. +25.5%). The company is benefiting from growing subscriber base thanks to a robust portfolio. Crackdown on password-sharing and the introduction of paid sharing in more than 100 countries, which represents more than 80% of Netflix’s revenue base, is also expected to aid growth.
Netflix’s diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content, has been driving its growth prospects. It now expects revenue growth to accelerate in the second half of 2023.
Nevertheless, stiff competition in the streaming space from the likes of Apple, Amazon Prime Video, HBO Max, Disney+, Peacock, Paramount+ and TikTok is a headwind. Netflix’s leveraged balance sheet and a higher streaming obligation are concerns.
(You can read the full research report on Netflix here >>>)
Other noteworthy reports we are featuring today include Medtronic plc and Marvell Technology, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.